Irinotecan and Carboplatin for Small-Cell Lung Cancer
Author Information
Author(s): A Kinoshita, M Fukuda, H Soda, S Nagashima, M Fukuda, H Takatani, M Kuba, Y Nakamura, J Tsurutani, S Kohno, M Oka
Primary Institution: Nagasaki University School of Medicine
Hypothesis
To determine the efficacy and toxicity of irinotecan combined with carboplatin in previously untreated small-cell lung cancer.
Conclusion
The combination of irinotecan and carboplatin is an active and well-tolerated regimen in cases of small-cell lung cancer.
Supporting Evidence
- 84% of patients showed an overall response rate.
- 28% of patients achieved a complete response.
- The median survival time was 15.0 months.
- Grade 3 or 4 toxicities were observed in 84% of patients.
- Neutropenia was the most common severe side effect.
Takeaway
Doctors tested a new medicine combination to help people with a type of lung cancer, and it worked well for many patients.
Methodology
Patients received irinotecan and carboplatin every four weeks, and their responses were evaluated after treatment.
Potential Biases
Potential biases may arise from the non-randomized design and the specific eligibility criteria.
Limitations
The study included a relatively small number of patients and was conducted at multiple institutions.
Participant Demographics
The study included 56 males and 5 females, with a median age of 68 years.
Statistical Information
P-Value
p<0.05
Confidence Interval
95% CI: 72–91%
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website